Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash Flows From Operating Activities:
Net loss	$ (2,813,312)	$ (2,828,318)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and Amortization	47,550	21,924
Stock Based Compensation	317,664	183,667
Changes in assets and liabilities:
Prepaid expenses and other receivables	206,716	(236,976)
Inventory	(186,137)	0
Accounts payable	21,259	155,286
Liability due to related party	(268,483)	359,842
Other liabilities and accrued expenses	110,780	(44,318)
Accrued interest receivable	0	70,527
Net cash used in operating activities	(2,563,963)	(2,318,366)
Cash Flows from Investing Activities:
Capitalized patent costs	(50,570)	(13,844)
Purchase of property and equipment	(162,615)	(43,216)
Fixed rate savings account	0	4,469,150
Net cash (used in) provided by investing activities	(213,185)	4,412,090
Cash Flows from Financing Activities:
Costs incurred in relation to ATM equity financing	(9,575)	(121,880)
Costs incurred in relation to public offering	0	(217,922)
Gross proceeds from issuance of common stock in relation to ATM financing	152,492	455,105
Gross proceeds from warrant exercise/unit option purchase	26,000	600
Gross proceeds from public offering	0	2,019,743
Repayments of note payable	(28,207)	0
Net cash provided by financing activities	140,710	2,135,646
Net (decrease) increase in cash	(2,636,438)	4,229,370
Effect of exchange rate changes on cash	(36,563)	(11,044)
Cash at beginning of period	3,740,664	822,335
Cash at end of period	1,067,663	5,040,661
Supplemental disclosure of non-cash financing activities:
Conversion of Series A preferred stock to common stock	0	137,324
Deferred offering costs included in accrued expenses	0	149,644
Gross amount of insurance funded through note payable	$ 132,352	$ 0